Dendreon Stock Up 1,341% Since the 2008-2009 Crash With Provenge
With stocks such as “Dendreon” having staged a comeback over the last two years amid unstable economic conditions should be able to pick up even more momentum when the economy generates higher levels of growth. The truth is, there could be considerable upside left in Dendreon shares — even though it has increased over 13x in value during the last two years.
The Great Recession Comeback is the recovery and return to prosperity in response to the economic meltdown which occurred during the last half of 2008 and the first four months of 2009. On March 9, 2009, which was the bottom set during the Financial Crisis, the S&P 500 index traded at 676.53 and has now climbed 658.57 points to close at 1335.10 on May 5, 2011 — over a 97% gain from the bottom but many investors missed out on much of the two-year bull market run that some experts say will continue into next year.
Investors are now considering how much more upside can possibly be left in the stock market which has rallied substantially higher over the past two years. Individual stocks will continue to rally based on how these companies have positioned themselves in the marketplace — positioning their companies growth on consumer reviews for their specific products and services.
Dendreon Corporation (NASDAQ: DNDN) – 1,341%
Dendreon stock price has jumped from $2.64 per share on March 9, 2009 to $38.05 per share as of May 5, 2011 — Hedge Fund manager George Soros owns Dendreon stock which is one of its top holdings. Dendreon’s flagship drug “Provenge“, which shot the stock up to new highs as it announced its results for its Phase III trial and as the FDA approved Provenge on April 29, 2010 for use in the treatment of advanced prostate cancer, is safe for now. Provenge is approved as a first-line treatment for metastatic castration-resistant prostate cancer before chemotherapy is used. It’s possible that doctors might prescribe Zytiga off-label for patients earlier in their disease progression, but they may run into resistance from insurance companies that aren’t willing to pay the high price.
Besides Dendreon being a “Takeover Target” — other “Biotech” companies being looked at as an “Acquisition Targets” with “Buyout Rumors” are Exelixis (NASDAQ: EXEL) which had hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested — if the reports are actually true, of course. In the less-risky category, we have Amarin (NASDAQ: AMRN) and Vertex Pharmaceuticals (NASDAQ: VRTX), which both have multiple successful “Phase 3 Trials” under their belts. Human Genome Sciences’ (NASDAQ: HGSI) lead drug has cleared the FDA hurdles but they haven’t been bought out — yet. Big Pharma is most likely waiting to see exactly how well the drugs will sell. Human Genome’s lupus drug Benlysta was approved last month, so we’re still months away from knowing how well the launch is going.
Tags: Acquisition Targets, Amarin, AMRN, Benlysta, Big Pharma, Biotech, Biotech Companies, Biotech Rumor, Biotechnology, Buyout Rumors, Dendreon, DNDN, EXEL, Exelixis, FDA, Financial Crisis, George Soros, Goldman Sachs, Great Recession, Hedge Fund, HGSI, Human Genome Sciences, Pharmaceutical, Phase 3 Trials, Provenge, S&P 500, Takeover Target, Vertex Pharmaceuticals, VRTX, XL184